We are monitoring the impact of COVID-19 & Recession alarm on Europe Ovarian Cancer Market Get in touch with us for detailed analysis Know More
Share on

Europe Ovarian Cancer Market Research Report – Segmented By Stage Of Cancer, Cancer Type, Diagnosis, Type Of Treatment & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1393
Pages: 181

Europe Ovarian Cancer Market Size (2022 to 2027)

The size of the Europe Ovarian Cancer Market is estimated to hike at a notable CAGR during the forecast period.

The increasing incidence of ovarian cancer drives the market. In addition, the need for more effective treatment options is pushing the growth of the market. Ovarian cancer is the eighth most commonly occurring cancer in women; hence, the growing geriatric population among women in European countries is expected to augment market growth. Aside from that, rising acceptance of new medicines and a robust development pipeline are expected to boost the European ovarian cancer therapeutics market. An increase in new ovarian cancer cases, the ease of use of new medications and therapies, and increased healthcare spending are driving the ovarian cancer market during the forecast period. 

Epithelial ovarian cancer (EOC), which develops from the ovary's epithelium, is the most prevalent kind of ovarian cancer. Ovarian cancer is one of the most common cancers in women in the Europe region. It kills more women than any other cancer of the female genital system, and it ranks fifth in overall cancer deaths among women. Unfortunately, this type of cancer is rarely diagnosed early, making treatment at a complicated stage difficult. 

Additionally, increasing investment and funding by the government and non-government organizations and technological advancements in the healthcare sector in the developed countries such as Germany, UK, Italy, Spain, and France are accelerating the market growth. 

Generics like paclitaxel and carboplatin dominate the market, although medicines like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to enhance revenue. However, the market may face a challenge in the development of more effective medicines. As a result, discovering new medicines to treat this form of cancer is expected to present substantial market potential.

In the pharmaceutical industry, firms are actively inventing and creating combination medicines to treat ovarian cancer. Combination medicines address complicated medical problems by combining two or more active pharmaceutical ingredients (APIs) into a single dose form.

However, the lack of appropriate technology for early detection of ovarian cancer is a key problem impeding the growth of the European ovarian cancer market. Also, the development of medicine with improved efficacy could pose a challenge for market growth.

This research report on the European ovarian cancer market has been segmented and sub-segmented into the following categories:

By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The European ovarian cancer market is expected to account for a significant share globally during the forecast period. The factors such as the increasing geriatric population, availability of advanced technology in the healthcare sector, and proliferation of ovarian cancer cases propelling the market growth. In addition, some popular medications' patent expiration may also help drive the market further by encouraging new entrants. During the projected period, these shifting dynamics are expected to increase the ovarian cancer market. In addition, the Major pharmaceutical companies in the region are investing in research and development activities that are expected to boost market growth.

Germany, United Kingdom, Spain, and France are regarded as promising countries with considerable market potential. Ovarian cancer is becoming more common, and it is expected to impact market growth positively. In addition, favorable medical care reforms, increased health awareness, a low-cost basis, and a lack of legal and cultural barriers contribute to the market growth in developed nations are over the forecast period.

In Europe, the United Kingdom has a significant proportion of the ovarian cancer diagnostics and treatments market share. Ovarian cancer is the most common cancer in women in the United Kingdom. Favorable reimbursement policies, advancing the healthcare sector, and infrastructure facilities are most likely to accelerate the market growth in the U.K.

KEY MARKET PLAYERS:

Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.       

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Stage Of Cancer                        

                                5.1.1 Stage I       

                                                5.1.1.1 Stage IA

                                                5.1.1.2 Stage IB

                                                5.1.1.3 Stage IC

                                5.1.2 Stage II     

                                                5.1.2.1 Stage IIA

                                                5.1.2.2 Stage IIB

                                                5.1.2.3 Stage IIC

                                5.1.3 Stage III    

                                                5.1.3.1 Stage IIIA

                                                5.1.3.2 Stage IIIB

                                                5.1.3.3 Stage IIIC

                                5.1.4 Stage IV    

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer               

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Primary Peritoneal Carcinoma        

                                5.2.3 Ovarian Stromal Tumors   

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type      

                                5.2.7 Market Attractiveness Analysis, By Type     

                                5.2.8 Market Share Analysis, By Type      

                5.3 Diagnosis                     

                                5.3.1 Introduction           

                                5.3.2 Physical Examination          

                                5.3.3 Blood Tests             

                                5.3.4 Ultrasound             

                                5.3.5 PET             

                                5.3.6 CT Scan     

                                5.3.7 MRI            

                                5.3.8 Human Chorionic Gonadotropin Test          

                                5.3.9 Biopsy       

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis          

                                5.3.11 Market Attractiveness Analysis, By Diagnosis         

                                5.3.12 Market Share Analysis, By Diagnosis          

                5.4 Treatment                  

                                5.4.1 Introduction           

                                5.4.2 Chemotherapy     

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy              

                                5.4.5 Surgery    

                                5.4.6 Immunotherapy   

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment          

                                5.4.9 Market Attractiveness Analysis, By Treatment         

                                5.4.10 Market Share Analysis, By Treatment       

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Aetera Zenteris Inc.                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Eli Lilly and Company                             

                8.3 Roche                           

                8.4 Amgen                         

                8.5 Janssen Pharmaceuticals, Inc.                             

                8.6 Bristol Myers Squibb Company                          

                8.7 Novogen, Inc.                            

                8.8 GlaxoSmithKline                      

                8.9 Boehringer Ingelheim                            

                8.10 AstraZeneca                            

                8.11 Genentech Inc.                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Europe Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  2. Europe Stage I Market, By Region, From 2022 - 2027 (USD Billion)
  3. Europe Stage II Market, By Region, From 2022 - 2027 (USD Billion)
  4. Europe Stage III Market, By Region, From 2022 - 2027 (USD Billion)
  5. Europe Stage IV Market, By Region, From 2022 - 2027 (USD Billion)
  6. Europe Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  7. Europe Primary Peritoneal Carcinoma Market, By Region, From 2022 - 2027 (USD Billion)
  8. Europe Ovarian Stromal Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  9. Europe Ovarian Germ Cell Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  10. Europe Epithelial Ovarian Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  11. Europe Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  12. Europe Physical Examination Market, By Region, From 2022 - 2027 (USD Billion)
  13. Europe Blood Tests Market, By Region, From 2022 - 2027 (USD Billion)
  14. Europe Ultrasound Market, By Region, From 2022 - 2027 (USD Billion)
  15. Europe PET Market, By Region, From 2022 - 2027 (USD Billion)
  16. Europe CT Scan Market, By Region, From 2022 - 2027 (USD Billion)
  17. Europe MRI Market, By Region, From 2022 - 2027 (USD Billion)
  18. Europe Human Chorionic Gonadotropin Test Market, By Region, From 2022 - 2027 (USD Billion)
  19. Europe Biopsy Market, By Region, From 2022 - 2027 (USD Billion)
  20. Europe Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  21. Europe Chemotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  22. Europe Radiation Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  23. Europe Hormonal Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  24. Europe Surgery Market, By Region, From 2022 - 2027 (USD Billion)
  25. Europe Immunotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  26. Europe Targeted Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  27. U.K. Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  28. U.K. Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  29. U.K. Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  30. U.K. Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  31. Germany Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  32. Germany Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  33. Germany Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  34. Germany Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  35. France Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  36. France Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  37. France Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  38. France Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  39. Italy Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  40. Italy Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  41. Italy Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  42. Italy Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  43. Spain Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  44. Spain Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  45. Spain Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  46. Spain Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample